KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Evolent Health (EVH) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $14.7 million.

  • Evolent Health's Share-based Compensation rose 184.52% to $14.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.2 million, marking a year-over-year decrease of 4469.4%. This contributed to the annual value of $39.7 million for FY2024, which is 186.42% down from last year.
  • Evolent Health's Share-based Compensation amounted to $14.7 million in Q3 2025, which was up 184.52% from $11.6 million recorded in Q2 2025.
  • Evolent Health's Share-based Compensation's 5-year high stood at $18.8 million during Q1 2024, with a 5-year trough of -$6.1 million in Q4 2024.
  • Over the past 5 years, Evolent Health's median Share-based Compensation value was $10.2 million (recorded in 2023), while the average stood at $8.9 million.
  • Its Share-based Compensation has fluctuated over the past 5 years, first skyrocketed by 19515.84% in 2022, then plummeted by 15767.24% in 2024.
  • Quarter analysis of 5 years shows Evolent Health's Share-based Compensation stood at $5.0 million in 2021, then surged by 195.16% to $14.6 million in 2022, then fell by 27.53% to $10.6 million in 2023, then plummeted by 157.67% to -$6.1 million in 2024, then soared by 340.1% to $14.7 million in 2025.
  • Its last three reported values are $14.7 million in Q3 2025, $11.6 million for Q2 2025, and $11.1 million during Q1 2025.